Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021

Incyte (INCY) PT Lowered to $92 at RBC Capital Following Earnings

May 4, 2021 12:51 PM EDT

RBC Capital analyst Brian Abrahams lowered the price target on Incyte (NASDAQ: INCY) to $92.00 (from $93.00) while maintaining a Sector Perform rating following reults.

The analyst commented, "A soft quarter for INCY from combined pandemic/seasonal oncology headwinds, though signs suggest to us... More